Nolomirole
Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 90060-42-7
- 分子式: C19H27NO4
- 分子量:333.42
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female rats were given single intraperitoneal injection of Monocrotaline (50 mg/kg) [5].
-
Dosage:0.25 mg/kg
-
Administration:Oral gavage (p.o.), twice a day for 21-25 days after Monocrotaline administration 3 days later, and then evaluated heart hypertrophy and neuroendocrine alterations.
-
Result:Significantly reduced hypertrophy of right atria (0.29 mg/g) and ventricles (1.62 mg/g), plasma levels of ANP and presence of pleural/peritoneal effusions and norepinephrine depletion of right ventricle (from 3.64 nmol /gww to 5.56 nmol/gww).
化学情報
-
CAS 番号 90060-42-7
-
分子量 333.42
-
分子式 C19H27NO4
-
SMILES
CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O
-
別名
CHF 1035 free base
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
純度とドキュメンテーション
参考文献
[1]. 1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476(1):145-155. [Content Brief]
[2]. 2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10(1):89-95. [Content Brief]
[3]. 3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15(2):139-45. [Content Brief]
[4]. 4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49(1):1-5. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Nolomirole 関連分類
HY-106973 関連分類
Powered by Bioz